Over recent years, multinational pharmaceutical companies have faced the challenge of developing new products and new markets in order to replace the significant revenues threatened by the loss of blockbuster patents. A key strategic response to this challenge has been a shift in attention towards emerging markets. Chris Toller of ChoiceOne, Uk shows why Asian regional studies have the potential to deliver significant efficiencies in terms of time and cost, and their data can potentially be used to support registration applications in different target countries.

 
http://jforcs.com/jcs/wp-content/uploads/2013/06/4-Clinical-Studies-in-Asia-Pacific-A-Regional-Percpective..pdf